Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
72
datasets available to search
ShareScore release 0.9.0
Dataset results
72 results for “silymarin”
Figure 4 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 4 The anti-proliferative assay (MTT) was used to examine the EMT-6/P and EMT-6/CPR cell lines' sensitivity to cisplatin at varying doses.
Figure 16 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 16 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum ALT level measured by (IU/L).
Figure 10 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 10 Folds increase in caspase-3 activity and apoptosis induction in concentrations of TQ (10 µM), silymarin (10 µM), and their combination in EMT-6/CPR cell line.
Figure 15 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 15 Changes of tumor sizes in EMT-6/CPR after dissection at day 10 in all groups compared to each other, n = 7.
Figure 14 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 14 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in EMT-6/CPR cell line.
Figure 21 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 21 Showed that there is no significant difference in serum creatinine between the healthy group and other treatment groups except cisplatin group. This graph was obtained by GraphPad Prism.
Figure 9 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 9 Demonstrates concentration of Caspase-3 in ng/ml in each treatment group along with the control group.
Figure 7 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 7 Anti-proliferation activity of several concentrations of TQ with 106.63 µM silymarin against EMT-6/CPR cell lines.
Figure 13 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 13 Shows that the percentage of change in tumor volume in EMT-6/CPR cell line was significant (P-value < 0.05) in all treatment groups except the silymarin group. This graph was obtained using GraphPad prism.
Figure 18 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 18 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum AST level measured by (IU/L).
Figure 12 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 12 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in EMT-6/P cell line.
Figure 6 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 6 Anti-proliferation activity of various concentrations of silymarin with 29.58 µM TQ against EMT-6/P cell lines.
Figure 5 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 5 Anti-proliferation activity of various concentrations of TQ with 142.40 µM silymarin against EMT-6/P cell lines.
Figure 17 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 17 Showed that there is no significant (ns) difference in serum ALT between the healthy group and other treatment groups. This graph was obtained by GraphPad Prism.
Figure 2 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 2 Anti-proliferation effect of TQ in single treatment against EMT-6/P and EMT-6/CPR cell lines.
Figure 20 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 20 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum creatinine level measured by (mg/dl).
Figure 19 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 19 Showed that there is no significant difference in serum AST between the healthy group and other treatment groups. This graph was obtained by GraphPad Prism.
Figure 11 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 11 Shows that the percentage of change in tumor volume in EMT-6/P cell line was significant (P-value < 0.05) in all treatment groups. This graph was obtained using GraphPad prism
Figure 3 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 3 Anti-proliferation effect of silymarin in single treatment against EMT-6/P and EMT-6/CPR cell lines.
Figure 8 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 8 Anti-proliferation activity of several concentrations of silymarin with 66 µM TQ against EMT-6/CPR cell lines.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.